comparemela.com

Latest Breaking News On - Dihydroergotamine mesylate - Page 1 : comparemela.com

Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor. | May 12, 2023

United statesDarren clineChristina tartagliaMichaelw kalbAdrian adamsMelyssa weibleImpel pharmaceuticals incAmerican academy of neurologyExchange commissionCincor pharma incElixir health public relationsImpel pharmaceuticalsCompany developmentsDevelopment rd expensesNet product revenueHost investor conference call today

Impel Pharmaceuticals Presents New Data at AAN 2023

New Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are.

Nada hindiyehJanhavi mohiteMelyssa weibleSheena auroraImpel pharmaceuticalsElixir health public relationsExchange commissionImpel pharmaceuticals incMetrodora instituteNew analysis indicates no drug interactionsClinical concernPredicted when recommended dosesShow concomitant useWere well toleratedLimited treatment emergent adverse eventsHeadache medicine

Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel. | March 24, 2023

United statesMelyssa weibleAdrian adamsDecember trudhesaJanhavi mohiteDrug administrationAmerican headache societyExchange commissionImpel pharmaceuticals incAmerican academy of neurologyDevelopment rd expensesElixir health public relationsImpel pharmaceuticalsProduct revenue finished yearHost investor conference call todayChief executive officer

Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update

15.08.2022 - Trudhesa TRx’s Grew 48% in Q2 2022 to Over 13K: Net Product Revenue Increased 59% Over Q1 2022 to $2.8 Million Sales Force Expanded by 50% to Capitalize on Prescription Momentum and Market Opportunity Company Reiterated Prescription Guidance Range .

United statesAdrian adamsChristina tartagliaMelyssa weibleTrudhesa dihydroergotamine mesylateCompany reiterated prescription guidanceImpel pharmaceuticalsExchange commissionDevelopment rd expensesImpel pharmaceuticals incAmerican headache societyElixir health public relationsClinical developmentCompany reiterated prescription guidance rangeProof of concept studyAutism spectrum

Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights

Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights - read this article along with other careers information, tips and advice on BioSpace

United statesUnited kingdomScottl zellerMichaelp watsonAdrian adamsChristina tartagliaKimberlyd nordstromMelyssa weibleCambridge universityImpel neuropharma incCompany guidanceDrug administrationExchange commissionCambridge university pressElixir health public relationsDihydroergotamine mesylate

vimarsana © 2020. All Rights Reserved.